WATERTOWN, Mass., April 06, 2016 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that company management will give a corporate presentation at the 15 th Annual Needham & Co. Healthcare Conference on Wednesday, April 13, 2016 at 11:20 a.m. Eastern Time at The Westin Grand Central Hotel in New York City.

A live audio webcast of the Needham presentation will be available on the company's website at http://ir.tphase.com/events.cfm.  An archived presentation will be available for 30 days.

About Tetraphase Pharmaceuticals, Inc.Tetraphase is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening MDR bacterial infections, including those caused by many of the MDR Gram-negative bacteria highlighted as urgent public health threats by the CDC. Tetraphase has created more than 3,000 novel tetracycline analogs using its proprietary technology platform. Tetraphase's pipeline includes three antibiotic candidates: eravacycline, its late-stage clinical candidate, TP-271 and TP-6076. Please visit www.tphase.com for more company information.

Investor Contacts:Tetraphase PharmaceuticalsTeri Dahlman617-600-7040tdahlman@tphase.comMedia Contact:Sam Brown Inc.Mike Beyer 312-961-2502mikebeyer@sambrown.comArgot PartnersSusan Kim212-600-1902susan@argotpartners.com

Primary Logo